Daily Stock Analysis, AMGN, Amgen Inc, priceseries

Amgen Inc. Daily Stock Analysis
Stock Information
Open
197.60
Close
195.84
High
198.35
Low
195.17
Previous Close
196.87
Daily Price Gain
-1.03
YTD High
210.97
YTD High Date
Aug 30, 2019
YTD Low
163.72
YTD Low Date
May 15, 2019
YTD Price Change
8.37
YTD Gain
4.46%
52 Week High
210.97
52 Week High Date
Aug 30, 2019
52 Week Low
163.72
52 Week Low Date
May 15, 2019
52 Week Price Change
2.29
52 Week Gain
1.18%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
144.65
Mar 17. 2017
155.58
32 Trading Days
7.56%
Link
LONG
Aug 28. 2017
161.92
Sep 22. 2017
174.03
18 Trading Days
7.48%
Link
LONG
Jun 3. 2019
171.15
Jul 8. 2019
182.48
24 Trading Days
6.62%
Link
LONG
Aug 8. 2019
183.93
Aug 23. 2019
198.29
11 Trading Days
7.81%
Link
Company Information
Stock Symbol
AMGN
Exchange
NasdaqGS
Company URL
http://www.amgen.com
Company Phone
(805)447-1000
CEO
Robert A. Bradway
Headquarters
Business Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320
Sector
Equity
Industry Category
Industry Group
CIK
About

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. Its products include aranesp, blincyto, corlanor, enbrel, epogen, imlygic, kyprolis, neulasta, neupogen, nplate, parsab, prolia, repatha, sensipar, vectibix, and xgeva. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.